Categoría: Geovanny Vicente

21 Acres: Historic Food Sales at Local Market amid Covid-19

WOODINVILLE, Wash., Aug. 3, 2020 /PRNewswire/ — A local retail farm market that buys from more than one hundred sustainable farmers and producers is seeing historic local food sales amid the coronavirus pandemic.

WOODINVILLE, Wash., Aug. 3, 2020 /PRNewswire/ — A local retail farm market that buys from more than one hundred sustainable farmers and producers is seeing historic local food sales amid the coronavirus pandemic.

Shoppers are seeking out alternatives to traditional grocery stores and rampant restaurant closures, says Caroline Ferguson, Farm Market Lead at 21 Acres Center for Local Food and Sustainable Living. These alternatives include King County farms, mills, and ranches that utilize time-honored techniques to improve soil health and draw carbon out of the atmosphere. «It’s a shift that could mark a turning point for local food and sustainable farming that works to mitigate climate change,» said Ferguson.

Since the COVID-19 outbreak became national news in early March, the Farm Market has seen sales nearly double over 2019’s numbers. Not only have total sales gone up, but customers are increasingly buying a large portion of their weekly groceries locally, instead of just specialty items; the average transaction size has increased 74% compared to 2019 according to Ferguson, with a record sales day set on July 3rd.

A recent survey of 21 Acres Farm Market customers showed that over 60% of respondents said that they have learned new cooking skills, from sourdough to cheesemaking to canning, since Governor Jay Inslee’s stay-at-home order went into effect. «The coronavirus has made many customers see the importance of food that was grown close to home,» said Ferguson. «People seem to be valuing a shorter supply chain from farm to table and are making local, seasonal food work for their families.»

«We have always shopped [locally],» said a customer, «but in the last year or two, the frequency had dropped off. My family and I have pledged to continue to shop and support local farmers even after this pandemic is over.»

«We’re hopeful that this sea change could benefit our local economy and the environment,» added Ferguson. «Since many small local farms use climate-conscious regenerative practices, this movement could lead to crucial advances in the fight to stop and reverse climate change.»

About 21 Acres:
21 Acres Center for Local Food & Sustainable Living is a center for agroecological education whose purpose is to promote the benefits of local food systems within the context of climate challenges. We explore the relationship between our natural and built environments through food and farm-based educational programs, workshops, and tours in the farm, market, and LEED Platinum certified building.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/21-acres-historic-food-sales-at-local-market-amid-covid-19-301104211.html

SOURCE 21 Acres Center for Local Food

South FL Doctor Dressed as Superhero Donates COVID-19 Safety Products to USPS Workers

FORT LAUDERDALE, Fla., Aug. 3, 2020 /PRNewswire/ — D.O.L Injury Centers is a federal workers compensation clinic easily recognized by its company mascot known as FED MAN. Since this pandemic started, the Clinic Director, Dr. Robert Kustin, has been seen in full superhero attire surprising USPS centers with complimentary shipments of hand sanitizer bottles and stations.

Dr. Kustin and the team at D.O.L Injury Centers understands the bravery displayed by the…

FORT LAUDERDALE, Fla., Aug. 3, 2020 /PRNewswire/ — D.O.L Injury Centers is a federal workers compensation clinic easily recognized by its company mascot known as FED MAN. Since this pandemic started, the Clinic Director, Dr. Robert Kustin, has been seen in full superhero attire surprising USPS centers with complimentary shipments of hand sanitizer bottles and stations.

Dr. Kustin and the team at D.O.L Injury Centers understands the bravery displayed by the USPS workers during this pandemic, or as they refer to them, «our unsung heroes.» The majority of their patients are USPS and TSA employees who need help with their job related injuries and filing the federal workers comp claims they need to receive treatment. «This is a very difficult time for the USPS. They are on the front lines day in and day out getting us our mail. We know what they are going through and want to show our appreciation and help keep them safe,» is Dr. Kustin’s response when asked why he’s been going out of his way to deliver these donations in a superhero outfit from head to toe in the hot Florida weather.

The first donation came on May 5, when 1,000 hand sanitizer bottles were delivered to the USPS center in Fort Lauderdale. On June 9, they delivered hand sanitizer stations to the USPS Miami distribution center, where he was awarded with a certificate of recognition for his kind donation. Dr. Kustin has more donations coming, but likes to surprise the USPS workers, in true superhero fashion.

Federal workers who are injured on the job, struggle with getting their claims with the Office of Workers’ Compensation approved so they can receive treatment. D.O.L Injury Centers specializes in not only providing medical care for injured Federal employees, but also full claim assistance so they can get back to work. For more info visit: https://dolinjurycenters.com/

Contact:
Danny Miranda, Director of PR
Pithy Marketing, LLC
(954) 993-6969
244588@email4pr.com
www.pithymarketing.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/south-fl-doctor-dressed-as-superhero-donates-covid-19-safety-products-to-usps-workers-301104649.html

SOURCE D.O.L Injury Centers

Hunt Heroes Foundation and Operation Homefront Collaborate to Support Military Families this Back to School Season

El PASO, Texas, Aug. 3, 2020 /PRNewswire/ — Hunt Heroes Foundation (HHF), the non-profit organization founded by Hunt Military Communities (HMC), announced today its support of Operation Homefront and its annual Back-to-School BrigadeⓇ program to bring school supplies to military families in advance of the upcoming 2020 school year. HHF will be delivering 1,850 backpacks filled with school supplies and distributing them throughout the month of August to HMC communities within the…

El PASO, Texas, Aug. 3, 2020 /PRNewswire/ — Hunt Heroes Foundation (HHF), the non-profit organization founded by Hunt Military Communities (HMC), announced today its support of Operation Homefront and its annual Back-to-School BrigadeⓇ program to bring school supplies to military families in advance of the upcoming 2020 school year. HHF will be delivering 1,850 backpacks filled with school supplies and distributing them throughout the month of August to HMC communities within the continental U.S.

Operation Homefront is a national nonprofit organization that provides military families with critical financial assistance, transitional and permanent housing, and recurring family support programs throughout the year. HMC has a committed and long-standing relationship with the military community and understands the challenges that affect military families. In light of the COVID-19 pandemic, this year’s Back-to-School BrigadeⓇ will have a different look relative to past programs, with a drive-through format, to adhere with federal, state, and local COVID-19 guidelines.

According to the National Retail Federation, in 2019, on average, families spent close to $700 per student for school supplies. In addition, many schools also asked parents to contribute up to $100 per family for general use classroom materials. When combined with other childcare costs, many military families face difficult choices about whether to ensure their children are well supplied for school or whether to purchase other essential items for their family, including clothing and food. 

«Operation Homefront is proud that Hunt Military Communities is helping bring our Back-to-School Brigade® program to military families in their communities,» said Robin Miller, Senior Director, Operation Homefront.  «With their support, we are able to distribute backpacks filled with school supplies to those who have given so much on behalf of all Americans and ensure their children have the tools for a successful start to the school year.»

Through the event, HHF aims to alleviate some of the financial burden military families face when getting their kids ready for school by providing backpacks with a variety of needed supplies, including pens, pencils, paper, scissors, and binders all tailored to the needs and grade levels of the children.

«We are honored to partner with Operation Homefront on an initiative that will support military families during this uniquely challenging back-to-school season,» said John Ehle, President of Hunt Military Communities. «It is our goal to make the process as seamless as possible for parents and make sure that their children are prepared to start the new school year, whether it’s virtually or in-person.»

This year, Operation Homefront will provide its 400,000th backpack with school supplies to a military child, saving military families more than $50 million in back-to-school expenses since the program launched in 2008.

About Hunt Heroes Foundation
Formed in 2018, the Hunt Heroes Foundation proudly serves military families, partners and communities through opportunities and ideas generated by our people and partnerships. Together, the HHF will discover new ways to ensure we help bring a positive change to the communities in which we live and work.

About Hunt Military Communities
Hunt Military Communities, the largest military housing owner, offers unsurpassed quality and service to more than 165,000 residents in approximately 52,000 homes on Navy, Air Force, Marine Corps, and Army installations across the USA. We do this through our core values: safety, kindness, efficiency, enthusiasm and selflessness and our 5-Star Service commitment.  With a 50-year legacy and a partnership with the Department of Defense, HMC strives to ensure the integrity of our military communities and the families who live there.  For more information, visit www.huntmilitarycommunities.com.

About Operation Homefront
Founded in 2002, Operation Homefront is a national nonprofit organization whose mission is to build strong, stable, and secure military families so that they can thrive – not simply struggle to get by – in the communities they have worked so hard to protect. Recognized for superior performance by leading independent charity oversight groups, over 90 percent of Operation Homefront expenditures go directly to programs that support tens of thousands of military families each year. Operation Homefront provides critical financial assistance, transitional and permanent housing and family support services to prevent short-term needs from turning into chronic, long-term struggles. Thanks to the generosity of our donors and the support from thousands of volunteers, Operation Homefront proudly serves America’s military families. For more information, visit OperationHomefront.org.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hunt-heroes-foundation-and-operation-homefront-collaborate-to-support-military-families-this-back-to-school-season-301104269.html

SOURCE Hunt Military Communities

The American Cancer Society Campaign Aims to Increase HPV Vaccination During Pandemic

ATLANTA, Aug. 3, 2020 /PRNewswire/ — In an effort to boost public health and help keep vaccinations on track in the midst of the coronavirus pandemic, the American Cancer Society is renewing

ATLANTA, Aug. 3, 2020 /PRNewswire/ — In an effort to boost public health and help keep vaccinations on track in the midst of the coronavirus pandemic, the American Cancer Society is renewing Mission: HPV Cancer Free, a campaign to eliminate HPV cancers as a public health problem, starting with cervical cancer.

The ongoing pandemic has created unprecedented challenges for healthcare providers, patients, and policymakers. One outcome from the past few months is dramatic declines in vaccination. A recent study showed a 71% drop in healthcare visits for 7-17-year-olds, ages when critical vaccines like Tdap, HPV, and meningitis are given. These declines put children and communities at greater risk for outbreaks of vaccine-preventable diseases.

HPV or human papillomavirus is a common virus that can cause six types of cancer. About 14 million people in the United States become infected with HPV each year. Eight out of ten people will get HPV at some point in their lifetime. Most infections become undetectable, but some can go on to cause cancer. HPV infection has no treatment, but a vaccine can prevent it.

«HPV vaccination offers the very rare opportunity to help prevent not just one but six types of cancer. Just two doses of this vaccine, given to kids at age 9-12, can prevent over 90% of HPV cancers,» said Debbie Saslow, PhD., managing director, HPV & GYN Cancers for the American Cancer Society.

HPV vaccination works best when given between ages 9 and 12. Vaccination at the recommended ages will prevent more cancers than vaccination at older ages. Children and young adults age 13 through 26 who have not been vaccinated, or who haven’t gotten all their doses, should get the vaccine as soon as possible. Both boys and girls can get infected with HPV. HPV vaccination helps protect boys from cancers of the throat, penis, and anus later in life. HPV vaccination helps protect girls from cancers of the cervix, throat, vagina, vulva, and anus later in life

The goal of Mission: HPV Cancer Free is to reach a vaccination rate of 80% of 13-year-olds in the United States by 2026.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-american-cancer-society-campaign-aims-to-increase-hpv-vaccination-during-pandemic-301103984.html

SOURCE American Cancer Society

L&L Candle Company Resolves Patent Infringement Investigation and Lawsuit Against MerchSource, LLC

BREA, Calif., Aug. 3, 2020 /PRNewswire/ — L&L Candle Company, LLC, which had filed patent infringement complaints against multiple companies in both the U.S. International Trade Commission and the United States District Court for the Western District of Texas this spring, announced that it has terminated those suits against MerchSource.

…

BREA, Calif., Aug. 3, 2020 /PRNewswire/ — L&L Candle Company, LLC, which had filed patent infringement complaints against multiple companies in both the U.S. International Trade Commission and the United States District Court for the Western District of Texas this spring, announced that it has terminated those suits against MerchSource.

«We’re extremely thrilled by this result,» L&L CEO Johnny Yang said.  «We have always believed our patented technologies produce the best LED candle products in the industry.  L&L has some of the strongest brands in the marketplace and we’re excited to have resolved our differences with MerchSource regarding flame sheet LED candles.»

The ITC investigation and Western District of Texas litigation will continue against the remaining defendants.  L&L is represented in the suits by the highly regarded U.S. law firm of Perkins Coie LLP, and in particular partners Thomas Millikan, Joseph Reid, and James Coughlan.  Founded in 1912, Perkins Coie LLP has more than 1,000 lawyers in 19 offices across the United States and Asia. The firm provides a full array of corporate, commercial litigation and intellectual property legal services to a broad range of clients.  With over 220 patent litigators and patent attorneys, Perkins Coie represents companies of all sizes in patent cases before district courts and the USITC across diverse industry sectors.  Perkins Coie’s attorneys have first chair trial and other patent litigation experiences in over 50 jurisdictions throughout the U.S.

Founded in 2017 as a joint venture between two of the preeminent artificial candle companies in the world, L&L has a patent portfolio of hundreds of patents and patent applications worldwide to protect the company and its innovations.  L&L is working hard to ensure that it is strategically positioned to help its partners and customers through this process.  For questions, please contact legal@llcandle.com.

Learn more about L&L at www.llcandle.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ll-candle-company-resolves-patent-infringement-investigation-and-lawsuit-against-merchsource-llc-301104174.html

SOURCE L&L Candle Co

Viasat Dynamic Video Encoding Enhances Satellite Connectivity for Intelligence, Surveillance and Reconnaissance Missions

CARLSBAD, Calif., Aug. 3, 2020 /PRNewswire/ — Viasat Inc. (NASDAQ: VSAT), a global communications company, announced today the availability of its Viasat Dynamic Video Encoding (DVE) capability, a new satellite communications technology enhancement that optimizes sensor data for military aircraft on Intelligence,…

CARLSBAD, Calif., Aug. 3, 2020 /PRNewswire/ — Viasat Inc. (NASDAQ: VSAT), a global communications company, announced today the availability of its Viasat Dynamic Video Encoding (DVE) capability, a new satellite communications technology enhancement that optimizes sensor data for military aircraft on Intelligence, Surveillance and Reconnaissance (ISR) missions. The new DVE capability allows aircraft to optimize their available bandwidth and video transmissions for high-speed, high-quality video feeds from the aircraft.

In today’s ISR missions, military aircraft often travel long legs from base to objective, where satellite return link data rates can change depending upon the location of the aircraft within the satellite footprint. As the aircraft traverse within a single beam and/or across higher data rate spot beam satellites, they are often unable to adjust sensor data rates to efficiently use the full satellite performance available. Recognizing this limitation, Viasat developed its DVE capability to optimize ISR data feeds based on satellite capability, as well as allowing this configuration-on-the-fly to occur across security boundaries.

Viasat’s DVE application will provide:

  • Video quality adaptation: encoder data rates dynamically change to fall within the maximum available return link data rates, enabling optimum use of available bandwidth—beam-edge-to-edge.
  • Bandwidth optimization: enables a communication channel between the Viasat modem and encoder, ensuring baseband applications get the full effect of the bandwidth required for ISR missions.
  • Configuration across security boundaries: the application takes advantage of a third-party Cross Domain Solution (CDS) that enables configuration to update across security boundaries. Additionally, Viasat’s DVE functionality can still be used to maximize the data rates, without a crypto requirement.
  • Congestion management: enables communication between the Viasat modem and Quality of Service (QoS)-enabled router, informing the router when bandwidth changes, which is needed to help manage congested links for critical services during beam-to-beam transitions.

«The Viasat DVE capability is game-changing—it increases the utility of Beyond Line of Sight (BLOS) sensor data for ISR missions when aircraft travel across different satellites, different beams of the same satellite or through varying signal strengths in the same beam, enabling a more efficient use of the satellite bandwidth,» said Ken Peterman, president, Government Systems, Viasat. «With Viasat DVE, we can enable military aircraft to maximize in-flight video quality and speeds as well as enable continuous video streaming, greater command and control (C2) and enhanced situational awareness to increase mission capability and success to the warfighter.»

For more specific product information about Viasat’s DVE capability, please visit Viasat’s website here.

About Viasat
Viasat is a global communications company that believes everyone and everything in the world can be connected. For more than 30 years, Viasat has helped shape how consumers, businesses, governments and militaries around the world communicate. Today, the Company is developing the ultimate global communications network to power high-quality, secure, affordable, fast connections to impact people’s lives anywhere they are—on the ground, in the air or at sea. To learn more about Viasat, visit: www.viasat.com, go to Viasat’s Corporate Blog, or follow the Company on social media at: Facebook, Instagram, LinkedIn, Twitter or YouTube.

Forward-Looking Statements
This press release contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933 and the Securities Exchange Act of 1934. Forward looking statements include statements about Viasat’s DVE capability to dynamically video encode; optimize bandwidth; configure across security boundaries and manage congestion. Readers are cautioned that actual results could differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ include: product defects, manufacturing issues or delays, contractual problems, regulatory issues, technologies that do not perform according to expectations; and increased competition and other factors affecting the government and defense sectors generally. In addition, please refer to the risk factors contained in Viasat’s SEC filings available at www.sec.gov, including Viasat’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. Viasat undertakes no obligation to update or revise any forward-looking statements for any reason.

Copyright © 2020 Viasat, Inc. All rights reserved. Viasat, the Viasat logo and the Viasat signal are registered trademarks of Viasat, Inc. All other product or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

 

Cision View original content:http://www.prnewswire.com/news-releases/viasat-dynamic-video-encoding-enhances-satellite-connectivity-for-intelligence-surveillance-and-reconnaissance-missions-301104477.html

SOURCE Viasat, Inc.

Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital

NEW HAVEN, Conn., Aug. 3, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) («Biohaven» or the «Company») announced today that the first patients were enrolled in the HEALEY ALS Platform Trial, which is evaluating the efficacy of three treatments including verdiperstat in people with amyotrophic lateral sclerosis («ALS»). Verdiperstat is a potential first-in-class, brain-penetrant, selective inhibitor of myeloperoxidase in development by Biohaven for the treatment of…

NEW HAVEN, Conn., Aug. 3, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) («Biohaven» or the «Company») announced today that the first patients were enrolled in the HEALEY ALS Platform Trial, which is evaluating the efficacy of three treatments including verdiperstat in people with amyotrophic lateral sclerosis («ALS»). Verdiperstat is a potential first-in-class, brain-penetrant, selective inhibitor of myeloperoxidase in development by Biohaven for the treatment of neurodegenerative diseases, including ALS and multiple system atrophy.

Irfan Qureshi, MD, Biohaven Vice President and Verdiperstat Development Lead, stated, «Biohaven continues to advance its novel pipeline across a variety of CNS diseases, and we are so pleased to enroll the first patient in a trial of verdiperstat in ALS. Given the tremendous burden of the disease on people with ALS and their families, more effective treatments are urgently needed. It is imperative that we rapidly and efficiently study promising new treatments such as verdiperstat, which targets brain inflammation. The HEALEY ALS Platform Trial will allow us to efficiently enroll this trial and determine if verdiperstat has the potential to help people with ALS.»

The HEALEY ALS Platform Trial is a major innovation in the field of ALS drug development that is aimed at accelerating the identification of effective new treatments. The HEALEY ALS Platform Trial is being conducted across over 50 sites by leading ALS experts from the Healey Center in collaboration with the Northeast ALS Consortium clinical trial network. In contrast to traditional trials that typically evaluate only one drug at a time, platform trials create an infrastructure for the ongoing study of multiple investigational drugs in parallel thereby maximizing resources and efficiency.

Merit Cudkowicz, MD, MSc, Director of the Healey Center and Chief of Neurology at Mass General, commented, «I am proud of our collaborators and grateful for the support of this courageous community. We are excited to be at this point and thankful to all teams involved for their invaluable input and support.»

The HEALEY ALS Platform Trial will study approximately 160 adults with ALS for each treatment. Participants will be randomized in a 3-to-1 ratio to be treated with verdiperstat 600 mg oral tablet twice daily or placebo for 24 weeks. The study’s primary efficacy endpoint will measure the change in disease severity from baseline to week 24 on the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients receiving treatment versus placebo. Secondary endpoints will include change in respiratory function, muscle strength, and survival. More information about the HEALEY ALS Platform Trial can be found at www.massgeneral.org/als.

«By testing multiple drugs at the same time, this platform trial will dramatically speed our search for effective ALS treatments for everyone living with ALS. The ALS Association is proud to be supporting this effort, and we are grateful to the Healey Center for their leadership,» said Calaneet Balas, President and CEO of The ALS Association. More information about the ALS Association can be found at www.als.org.

ALS is a progressive, life-threatening and rare neuromuscular condition that affects approximately 30,000 people in the United States. ALS is characterized by the loss of motor neurons in the brain, brainstem, and spinal cord that leads to progressive muscle weakness and difficulties in speaking, swallowing, and breathing. There are currently limited treatment options and no cure for ALS.

About Verdiperstat

Verdiperstat (BHV-3241) is an investigational first-in-class, potent, selective, brain-penetrant, and myeloperoxidase (MPO) enzyme inhibitor that Biohaven is developing for the treatment of neurodegenerative diseases.  Verdiperstat may help preserve neurons through inhibition of MPO-induced pathological oxidative stress and inflammation that contribute to cellular injury in neurodegenerative diseases such as ALS and multiple system atrophy (MSA). Biohaven licensed verdiperstat (BHV-3241) from AstraZeneca in September 2018, where it was known as AZD3241. Biohaven recently announced completion of enrollment in the M-STAR study, a Phase 3 clinical trial to assess the safety and efficacy of verdiperstat in MSA. Additional details can be found at clinicaltrials.gov/ct2/show/NCT03952806. Verdiperstat has received Orphan Drug and Fast Track designations for MSA from the US FDA, as well as Orphan Drug designation from the European Medicines Agency. More information about the HEALEY ALS Platform Trial can be found at www.massgeneral.org/als and clinicaltrials.gov/ct2/show/NCT04436510. More information about can be found at the Company’s website: www.biohavenpharma.com/science-pipeline/mpo/verdiperstat.

About Biohaven

Biohaven is a biopharmaceutical company focused on the development and commercialization of innovative best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases. Biohaven’s neuroinnovation portfolio includes FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer’s disease, and spinocerebellar ataxia; and myeloperoxidase inhibition for multiple system atrophy and amyotrophic lateral sclerosis. For more information, visit www.biohavenpharma.com.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Biohaven’s management. All statements, other than statements of historical facts, included in this press release, including the expected enrollment for Biohaven’s pivotal trial of verdiperstat, the potential results of Biohaven’s pivotal trial of verdiperstat in ALS, the potential role of verdiperstat in ALS, the possible benefits of verdiperstat as a disease-modifying therapy for ALS patients, as well as the timetable for the topline data and completion of trials, are forward-looking statements. The use of certain words, including the «believe» and «will» and similar expressions are intended to identify forward-looking statements. Biohaven may not actually achieve the plans and objectives disclosed in the forward-looking statements and you should not place undue reliance on Biohaven’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements, including uncertainties relating to the future clinical success of troriluzole. Additional important factors to be considered in connection with forward-looking statements are described in the «Risk Factors» section of Biohaven’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2020 and Biohaven’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the Securities and Exchange Commission on May 7, 2020. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Biohaven Contact

Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-enrollment-of-first-patients-in-pivotal-healey-als-platform-trial-including-verdiperstat-conducted-by-healey-center-for-als-at-massachusetts-general-hospital-301104359.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor

FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that tenapanor has been named a finalist in the Fierce Innovation Awards in the category of biotech innovation in a class of therapies identified by experts to have potential for significant impact in the industry. Tenapanor, discovered and…

FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that tenapanor has been named a finalist in the Fierce Innovation Awards in the category of biotech innovation in a class of therapies identified by experts to have potential for significant impact in the industry. Tenapanor, discovered and developed by Ardelyx, is a first-in-class therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis that is supported by three successful Phase 3 studies. The selection criteria for the award included: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. 

«We are thrilled to be recognized for the scientific innovation that exemplifies tenapanor, especially by the group of distinguished drug developers from major biopharmaceutical companies that participated in the award review,» said Mike Raab, president and chief executive officer of Ardelyx. «It is especially rewarding to see that the novel technological approach underlying tenapanor has translated into a promising therapeutic for the many patients with hyperphosphatemia. There is a high unmet need for new therapies that can effectively control phosphorus levels in patients with CKD on dialysis. These patients have up to a 38% increase in the relative risk of hospitalization due to cardiovascular events and up to a 102% increase in the relative risk of mortality. We are motivated and inspired by the possibility to help these patients with tenapanor.» 

The Fierce Innovation Awards – Life Sciences Edition 2020 is a peer reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma. The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharma companies. The awards program’s applications were reviewed by an exclusive panel of executives from major biotech and pharma companies including Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions and PPD. Winners will be announced in the 2020 Innovation Report set to publish by Fierce Life Sciences on September 14, 2020.   

About Tenapanor for Hyperphosphatemia
Tenapanor, discovered and developed by Ardelyx, is a first-in-class, proprietary, oral medicine for which the company has submitted an NDA to the FDA for the control of serum phosphorus in adult patients with CKD on dialysis. Tenapanor has a unique mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). This results in a conformational change of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate at the primary pathway of phosphate absorption. Three successful Phase 3 studies demonstrating tenapanor’s ability to reduce phosphate levels, as either monotherapy or as part of a dual mechanism approach with phosphate binders, have been reported.

About Hyperphosphatemia
Hyperphosphatemia is a serious condition resulting in an abnormally elevated level of phosphorus in the blood that is estimated to affect more than 745,000 dialysis patients in major developed countries. The kidney is the organ responsible for regulating phosphorus levels, but when kidney function is significantly impaired, phosphorus is not adequately eliminated from the body. As a result, hyperphosphatemia is a nearly universal condition among people with CKD on dialysis. Despite treatment with phosphate binders (the only approved therapy for hyperphosphatemia), approximately 70% of CKD patients on dialysis continue to experience elevated phosphorus levels at any point in time (Spherix Global Insights: RealWorld Dynamix, Dialysis 2018). Phosphorus levels greater than 5.5 mg/dL have been shown to be an independent risk factor for cardiovascular morbidity and mortality in patients requiring dialysis (Block 2004), and internationally recognized treatment guidelines recommend lowering elevated phosphate levels toward the normal range (<4.6mg/dL).

About Ardelyx, Inc.
Ardelyx is focused on developing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiovascular diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company submitted an NDA to the FDA on June 30, 2020. Ardelyx is also advancing RDX013, a potassium secretagogue program, for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in the respective territories.

Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including statements regarding the potential for tenapanor to reduce phosphate levels as either monotherapy or as part of a dual mechanism approach with phosphate binders. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties associated with the regulatory approval process and uncertainties in the drug commercialization process. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx’s business in general, please refer to Ardelyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2020, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ardelyx-selected-as-a-finalist-in-the-fierce-innovation-awards-for-the-development-of-its-first-in-class-product-candidate-tenapanor-301104270.html

SOURCE Ardelyx

ERT Leader Recognized for Exemplifying Values, Commitment to Improving Patient Health

PHILADELPHIA, Aug. 3, 2020 /PRNewswire-PRWeb/ — ERT, the global leader in clinical endpoint data collection, today announced Jim Corrigan, President and CEO has been named one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice. Representing a broad cross-section of industry…

PHILADELPHIA, Aug. 3, 2020 /PRNewswire-PRWeb/ — ERT, the global leader in clinical endpoint data collection, today announced Jim Corrigan, President and CEO has been named one of the 100 most inspiring individuals in the life-sciences industry by PharmaVoice. Representing a broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired their colleagues and affected positive changes in their organizations.

Jim is recognized for his dedication to supporting the industry during a time of significant change by exemplifying his core values which include ensuring employee well-being, instilling a culture of accountability and trust, and an unwavering focus on helping ERT’s customers develop new treatments to improve the health of patients worldwide.

Jim has driven significant advancements in clinical trial methodologies that help global biopharmaceutical companies bring new treatments to patients through more efficient and effective data collection. Since COVID-19 stay-home mandates have interrupted some important clinical development programs, Jim has led ERT to accelerate its delivery of virtual data collection tools, ensuring patient safety and enabling clinical trial continuity regardless of their physical access to investigative sites.

«Jim’s ability to inspire innovative thinking enables ERT to continually exceed customers’ expectations and deliver the solutions they need to meet their complex needs,» said Eran Broshy, Chairman of ERT’s Board of Directors. «We’re very proud of his accomplishments and applaud him – as well as all of the individuals being recognized – for this well-deserved recognition.»

For more information, visit ert.com

About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs, and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter.

 

SOURCE ERT

Eirene N. Salvi wins 2019-2020 ISBA Diversity Leadership Award

CHICAGO, Aug. 3, 2020 /PRNewswire-PRWeb/ — Salvi, Schostok & Pritchard P.C. is proud to announce the Illinois State Bar Association’s Diversity Leadership Council has selected attorney Eirene Nakamura Salvi as the recipient of the 2019-2020 Diversity Leadership Award.

Each year, the Diversity Leadership Award recognizes a person or organization that has made significant contributions to the advancement of diversity within the

CHICAGO, Aug. 3, 2020 /PRNewswire-PRWeb/ — Salvi, Schostok & Pritchard P.C. is proud to announce the Illinois State Bar Association’s Diversity Leadership Council has selected attorney Eirene Nakamura Salvi as the recipient of the 2019-2020 Diversity Leadership Award.

Each year, the Diversity Leadership Award recognizes a person or organization that has made significant contributions to the advancement of diversity within the Illinois legal community, its judiciary and/or the Illinois State Bar Association.

«Diversity in the Plaintiffs’ bar and many other walks of life has not been appreciated the way it should be. I cannot think of anyone more dedicated to bringing attention to the importance and value that comes with a diverse environment, whether personal or professional, than Eirene. She has and will continue to be a leader in this regard and has impacted Salvi, Schostok & Pritchard in her short time at the firm,» Salvi, Schostok & Pritchard Partner Brian L. Salvi said.

Eirene Nakamura Salvi is a co-chair and founding member of the Chicago Committee of the Japanese American Bar Association. The group provides a special forum for members of the legal profession with interests and ties to the Japanese American community to discuss issues, network, and serve the community. Ms. Salvi is also an officer of the board of Lawyers Lend-A-Hand to Youth, an organization that channels the legal community’s resources to promote one-to-one mentoring and tutoring programs in disadvantaged Chicago communities, with its primary initiative being a tutoring program for elementary students in Englewood. Ms. Salvi serves on the newly established Diversity & Inclusion Committee of the Illinois Trial Lawyers Association, which aims to develop strategies and programs to increase minority membership and participation in leadership roles and joint programs with other minority bar associations.

During law school, Ms. Salvi assisted a professor in writing an amicus curiae brief on behalf of the families of victims of terrorism against the Islamic State of Iran as a state sponsor of terrorism. She also worked as an extern at the National Immigrant Justice Center, where she filed a successful application for humanitarian parole for a victim of gross human rights violations in the Central Democratic Republic of Congo. During her time at Notre Dame Law School, she also served as vice president of the Asian Law Students Association and was active in the Black Law Students Association and Hispanic student groups.

Born in Japan to a Japanese father and Mexican mother, Ms. Salvi moved to California with her family when she was a young child. She speaks four languages—English, Japanese, Spanish, and French.

Eirene and recipients of various other awards from the ISBA will be honored in the ISBA’s August issue of the Bar Journal.

For more information, please contact Marcie Mangan at (312) 372-1227 or mmangan@salvilaw.com.

 

SOURCE Salvi, Schostok & Pritchard